Skip to main content

Scotiabank Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)

Tipranks - Tipranks - Wed Mar 11, 6:11AM CDT

Scotiabank analyst Louise Chen maintained a Buy rating on Vertex Pharmaceuticals today and set a price target of $558.00.

Claim 70% Off TipRanks Premium

Chen covers the Healthcare sector, focusing on stocks such as Merck & Company, Regeneron, and AbbVie. According to TipRanks, Chen has an average return of 4.7% and a 47.94% success rate on recommended stocks.

In addition to Scotiabank, Vertex Pharmaceuticals also received a Buy from Citi’s Geoff Meacham in a report issued today. However, on the same day, Needham maintained a Hold rating on Vertex Pharmaceuticals (NASDAQ: VRTX).

See the top stocks recommended by analysts >>

Based on Vertex Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $3.23 billion and a net profit of $1.19 billion. In comparison, last year the company earned a revenue of $2.91 billion and had a net profit of $913 million

Read More on VRTX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).